

# Genetic polymorphisms of cytochrome P4501A1 and oesophageal squamous-cell carcinoma in Taiwan

M-T Wu<sup>\*,1,2</sup>, J-M Lee<sup>3</sup>, D-C Wu<sup>4</sup>, C-K Ho<sup>1,2</sup>, Y-T Wang<sup>1</sup>, Y-C Lee<sup>3</sup>, H-K Hsu<sup>5</sup> and E-L Kao<sup>6</sup>

<sup>1</sup>Graduate Institute of Occupational Safety and Health, Kaohsiung Medical University, Taiwan; <sup>2</sup>Department of Occupational Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; <sup>3</sup>Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan; <sup>4</sup>Department of Gastroenterology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; <sup>5</sup>Department of Chest Surgery, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan; <sup>6</sup>Department of Chest Surgery, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan

Several *in vitro* studies have demonstrated that genetic polymorphisms result in functionally significant changes in cytochrome p4501A1 (either CYP1A1 MspI or exon 7) but the few epidemiologic studies of these polymorphisms in oesophageal squamous-cell carcinoma have been inconclusive. These inconclusive results motivated us to further examine the relationship between CYP1A1 MspI and exon 7 polymorphisms and risk of oesophageal cancer. In total, 146 cases of oesophageal squamous-cell-carcinoma and 324 control cases (a total of 470 cases) were genotyped from records at three Taiwan hospitals. No significant association was noted for the CYP1A1 MspI polymorphism variable between carcinoma and control cases. In contrast, the frequency of Ile/Ile, Ile/Val, and Val/Val in exon 7 was 68 (46.6%), 62 (42.5%), and 16 (11.0%) in carcinoma cases and 179 (55.3%), 127 (39.2%), and 18 (5.6%) in control cases, respectively. After factoring out other potential contributing factors, patients with Val/Val showed a 2.48 (95% CI=1.15–5.34) greater risk of developing oesophageal cancer than those with Ile/Ile. A slightly (albeit not significantly) greater risk was identified in subjects with Ile/Val (OR=1.34; 95% CI=0.86–2.07). These findings suggest that an exon 7 polymorphism, not a MspI polymorphism, in CYP1A1 may be pivotal in the development of oesophageal cancer.

British Journal of Cancer (2002) 87, 529–532. doi:10.1038/sj.bjc.6600499 www.bjcancer.com  
© 2002 Cancer Research UK

**Keywords:** oesophageal cancer; squamous-cell-carcinoma; cytochrome p4501A1; genetic polymorphism

The CYP1A1 gene code in the aryl hydrocarbon hydroxylase (AHH) enzyme is closely associated with the metabolism of polycyclic aromatic hydrocarbons (PAHs) carcinogens (Crofts *et al*, 1994). Previous studies have suggested that variant alleles of CYP1A1 MspI polymorphism are associated with malignancies, particularly lung cancer (Kawarjiri *et al*, 1990; Nakachi *et al*, 1991; Hayashi *et al*, 1992; Xu *et al*, 1996). As reported by Bartsch *et al* (2000), no association was identified between CYP1A1 MspI and exon 7 polymorphisms and oesophageal cancer risk in a series of studies done on populations of Caucasians and Japanese (Lucas *et al*, 1996; Hori *et al*, 1997; Morita *et al*, 1997; van Lieshout *et al*, 1999). However, Nimura *et al* (1997) studied 89 oesophageal carcinoma patients and 137 cancer-free control patients in an ethnically Chinese population and reported that heavy smokers with Val/Val genotypes of CYP1A1 exon 7 had a three-fold risk of developing oesophageal cancer as compared to those with Ile/Ile genotypes. A subsequent study by Roth *et al* (2000) did not find any significant effect of CYP1A1 exon 7 polymorphisms in 56 individuals with mild or moderate squamous dysplasia and 56 control individuals (a relatively small sample size) from Linxian, a region of high oesophageal cancer risk in China. Recently, Wang *et al* (2002) genotyped 127 oesophageal cancer cases and 101

controls and found that individuals with the CYP1A1 Val/Val genotype had a higher risk of developing oesophageal cancer than those with Ile/Ile (OR=2.48, 95%CI=1.12–5.54). In view of the apparently significant influence of ethnicity in previous studies, we have examined further the role of CYP1A1 MspI and exon 7 polymorphisms in oesophageal cancer risk in Taiwan.

## MATERIALS AND METHODS

### Selection of cases and controls

Over the four-year period of this study, we recruited 146 patients with pathologically-proven oesophageal squamous-cell-carcinoma undergoing treatment at three hospitals in Taiwan, including the National Taiwan University Hospital, the Kaohsiung Medical University Hospital, and the Kaohsiung Veterans General Hospital. Concurrently, the preventive medicine department at each hospital did their best to also recruit 1–4 malignancy-free subjects per recruited carcinoma patient as healthy controls (*n*=324). Healthy control subjects were selected based on being the same gender as the recruited carcinoma patient and being in the hospital during the same time and of roughly the same age ( $\pm 3$  years). Subjects in this study were interviewed by trained interviewers using a standardized questionnaire to collect demographic and substance use (cigarette, alcohol, and areca) information. This study was approved by National Taiwan University's IRB Hospital. Informed consent was obtained from all subjects.

\*Correspondence: M-T Wu, Graduate Institute of Occupational Health and Safety, Kaohsiung Medical University, 100 Shih-Chuan 1st Road, Kaohsiung, Taiwan; E-mail: mingtsangwu@yahoo.com  
Received 9 May 2002; revised 17 June 2002; accepted 17 June 2002

### CYP1A1 MspI polymorphism

The *MspI* polymorphism in the *CYP1A1* 3' flanking region was determined using PCR and RFLP (Wu *et al*, 1998). The DNA sample was amplified with 2 primers: 5'-CAGTGAAGAGGTG-TAGCCGC-3' (upstream) and 5'-TAGGAGTCTTGTCTCATGCC-3' (downstream) (Perkin Elmer, Taipei, Taiwan). Amplification was performed by initial denaturation at 94°C for 5 min, followed by 30 cycles at 94°C for 1 min, 61°C for 1 min, 72°C for 1 min, and a final extension at 72°C for 7 min.

The 10- $\mu$ l amplification result was digested using 3 units *MspI* (New England Biolabs, Beverly, MA, USA). When an *MspI* restriction site was present, the fragment of 340 bp was digested into two lengths of 140- and 200-bp. Homozygous wild-type individuals lacked the 140- and 200-bp fragment, and heterozygous individuals had three bands; homozygous-rare allele individuals lacked the large parent band while showing the smaller bands.

### CYP1A1 Ile/Val polymorphism

The *BsrDI* polymorphism in *CYP1A1* exon 7 was determined using PCR and RFLP, according to the method used by Cascorbi *et al* (1996), albeit with slight modifications. The DNA sample was amplified with two primers: 5'-CTGTCTCCCTCTGGTTACAG-GAAGC-3' (upstream) and 5'-TTCCACCCGTTGCAGCAGGATA-GCC-3' (downstream) (Perkin Elmer, Taipei, Taiwan). Amplification was performed by initial denaturation at 95°C for 5 min, followed by 35 cycles at 95°C for 30 s, 73.5°C for 30 s, 72°C for 30 s, and a final extension at 72°C for 7 min. The final product was digested by *BsrDI*. When a *BsrDI* restriction site was present, the fragment of 204-bp was digested into two lengths of 65- and 139-bp. Individuals with *Ile/Ile* had the 65- and 139-bp fragment, heterozygous individuals had three bands; and individuals with *Val/Val* retained the larger parent bands (204-bp).

### Laboratory QA/QC

We included one positive control and one negative control samples in each genotyping set (~10 samples). The positive control sample was included to ensure complete digestion of the PCR product by restriction enzymes. The negative control was placed with the same reagents as those used with actual samples, with the exception of DNA templates.

### Statistical analysis

The gene frequency and Hardy-Weinberg equilibrium tests were conducted, with results entered into multiple logistic regression models to determine, after adjustments had been made for other factors of influence, the level of association between *CYP1A1 MspI* and *exon 7* polymorphisms and oesophageal cancer risk. Factors of influence (covariates) in the models included the variables of age (>65 years and  $\leq$ 65 years), gender, education level ( $\geq$ college, high school, and  $\leq$ elementary school), and race (Fukienese, Mainlander, and 'other'). The data were analysed using the SAS statistical package and all *P*-values were two-sided.

## RESULTS

The mean age for carcinoma and control cases was 60.6 and 61.2 years, with an associated age range of 37 to 81 and 34 to 84 years, respectively. The habitual use of cigarettes (*P*=0.03), alcohol (*P*=0.03), and areca (*P*<0.01) provided the most significant predictors of oesophageal cancer risk (Table 1).

The frequency of *MspI* polymorphism in wild-type, heterozygous variant, and homozygous variant control cases was 136 (42.0%), 146 (45.1%), and 42 (13.0%), respectively. The gene frequency of

**Table 1** Demographic characteristics of oesophageal cancer

Variables	Cases n (%)	Controls n (%)	P value
Gender			
Male	133 (91.1)	298 (92.0)	0.75
Female	13 (8.9)	26 (8.0)	
Age (in years)			
$\leq$ 65	97 (66.4)	214 (66.1)	0.93
>65	49 (33.6)	110 (33.9)	
Education			
$\leq$ primary school	34 (23.3)	103 (31.8)	0.15
High schools	33 (22.6)	59 (18.2)	
$\geq$ College	79 (54.1)	162 (50.0)	
Race			
Fukienese	114 (78.1)	257 (79.3)	0.93*
Mainlanders	28 (19.2)	57 (17.6)	
Other	4 (3.1)	10 (2.7)	
Cigarette smoker			
Non-smoker	64 (43.8)	177 (54.6)	0.03
Smokers	82 (56.2)	147 (45.4)	
Alcohol consumption			
Non-drinkers	82 (56.2)	215 (66.4)	0.03
Drinkers	64 (43.8)	109 (33.6)	
Areca consumption			
Non-chewers	115 (78.8)	294 (90.7)	<0.01
Chewers	31 (21.2)	30 (9.3)	

\*Fisher exact test.

the variant allele was 35.5%. The frequency of *Ile/Ile*, *Ile/Val*, and *Val/Val* in *exon 7* among controls was 179 (55.3%), 127 (39.2%), and 18 (5.6%), respectively. The gene frequency of the variant allele (*Val*) was 25.2%. The distribution of the different genotypes in both *MspI* and *exon 7* polymorphisms among the 324 control cases closely conformed to Hardy-Weinberg expected frequencies ( $\chi^2=0.04$ ; d.f.=2; *P*=0.98 and  $\chi^2=0.28$ ; d.f.=2; *P*=0.87, respectively).

The frequency of *Ile/Ile*, *Ile/Val*, and *Val/Val* in *exon 7* was 68 (46.6%), 62 (42.5%), and 16 (11.0%) in carcinoma cases and 179 (55.3%), 127 (39.2%), and 18 (5.6%) in control cases, respectively. As lists of those genotypes with elevated oesophageal cancer risk were similar both after adjusting only for substance use and after adjusting for substance use along with age, gender, education, and race, we present here the results for the latter category. Compared to those with *Ile/Ile*, subjects carrying *Val/Val* had a 2.34-fold risk (95% CI=1.13–4.85) of developing oesophageal cancer. After adjusting for other potential confounding factors, the result remained similar (OR=2.48; 95% CI=1.15–5.34) (Table 2). The results show even a slightly greater risk after further adjusting for *MspI* polymorphism (OR=2.71; 95% CI=1.75–6.38). A slight, but not significant, risk elevation was found in subjects with *Ile/Val* both before and after adjusting for confounding factors (OR=1.29 and 1.34; 95% CI=0.85–1.94 and 0.86–2.07, respectively). In contrast, we found no significant polymorphic effect of *CYP1A1 MspI* on oesophageal cancer (Table 2).

## DISCUSSION

The results of this study found that those cases with the *CYP1A1 Val/Val* genotype had a 2.34 times higher risk (95% CI=1.13–4.85) of developing oesophageal cancer than those with the *Ile/Ile* genotype. In contrast, the *CYP1A1 MspI* genetic polymorphism was not found to be associated with elevated oesophageal cancer risk. Several studies on ethnic Japanese populations reported no association between *CYP1A1 MspI* and *exon 7* polymorphisms and risk of oesophageal cancer (Hori *et al*, 1997; Morita *et al*, 1997; van Lieshout *et al*, 1999). However, their small case popula-

**Table 2** CYP1A1 genotypes and oesophageal cancer

CYP1A1	Cases n (%)	Controls n (%)	OR (95% CI)	AOR (95% CI)
<i>MspI</i>				
Wild-type	60 (41.1)	136 (42.0)	1.00	1.00
Heterozygous variant	65 (44.5)	146 (45.1)	1.01 (0.66, 1.54)	0.98 (0.63, 1.53)
Homozygous variant	21 (14.4)	42 (13.0)	1.13 (0.62, 2.08)	1.24 (0.65, 2.36)
<i>Exon 7*</i>				
<i>Ile/Ile</i>	68 (46.6)	179 (55.3)	1.00	1.00
<i>Ile/Val</i>	62 (42.5)	127 (39.2)	1.29 (0.85, 1.94)	1.34 (0.86, 2.07)
<i>Val/Val</i>	16 (11.0)	18 (5.6)	2.34 (1.13, 4.85)	2.48 (1.15, 5.34)

AOR: After adjusting for age (>65 vs ≤65 yrs), education level (≤primary school, high school, ≥college), ethnicity (Fukienese, Mainlander, Other), cigarette habit (yes vs no), alcohol consumption (yes vs no), and areca consumption (yes vs no). \*Trend test,  $P=0.02$ .

tion (less than 100 oesophageal cancer cases were investigated) may not be sufficient to make a scientific determination regarding genotype significance. Although Roth *et al* (2000) found no significant effect of CYP1A1 *exon 7* polymorphisms on either the 56 individuals with mild or moderate squamous dysplasia or the 56 control cases from a high oesophageal cancer risk region with an ethnic Chinese population, Nimura *et al* (1997) found subjects in China with heavy smoking habits had a three times higher frequency of the CYP1A1 *Val/Val* variant. Recently, Wang *et al* (2002) also found that individuals with the CYP1A1 *Val/Val* genotype had a higher risk of developing oesophageal cancer than those with the *Ile/Ile* (OR=2.48, 95% CI=1.12–5.54). Our findings approximate the Wang *et al* (2002) findings.

Human cancers, e.g., gastrointestinal cancers, were suggested to be the result of the activation of procarcinogens into carcinogens (Nakajima *et al*, 1996). Murray *et al* (1994) and Nakajima *et al* (1996) examined the expression of cytochrome P450s in human esophagi with squamous-cell carcinomas. Both studies found that the amount of cytochrome P450 1A1 expression in tumorous tissue to be significantly higher than that in non-tumorous tissues. These two findings suggest that the inducible CYP1A1 gene might contribute to oesophageal cancer development. In two *in vitro* studies, Kiyohara *et al* (1996) examined the relationship between AHH inducibility (3-methylcholanthrene (MC)-induced AHH activity/non-induced AHH activity) and the frequency of CYP1A1 *MspI* and *exon 7* polymorphisms in peripheral lymphocytes in 84 healthy Japanese male subjects *in vitro*. They found the age-adjusted AHH inducibility (mean ± standard error) of the wild-type, heterozygous, and homozygous variants of the CYP1A1 *MspI* gene to be  $4.89 \pm 0.36$ ,  $4.82 \pm 0.29$ , and  $13.61 \pm 1.44$ , respectively. Furthermore, the homozygous variants had significantly higher AHH inducibility than the combined wild-type and heterozygous variants. However, no association was found between AHH indu-

cibility and CYP1A1 *exon 7* polymorphisms. In contrast, Crofts *et al* (1994) measured gene expression levels and AHH enzymatic activity levels of *MspI* and *exon 7* polymorphisms in mitogen-stimulated lymphocytes in 51 healthy subjects. They reported that subjects with the *exon 7* polymorphism (variant alleles) ( $n=12$ ) had a relative level of CYP1A1 mRNA inducibility (induced/basal) of  $9.0 \pm 1.7$ , versus  $5.9 \pm 0.6$  in people with the wild-type alleles ( $n=39$ ). However, variant genotypes at the *MspI* site had no effect on CYP1A1 gene induction. Our results in this epidemiologic study align more closely with those obtained by Crofts *et al* (1994).

Our previous study found the prevalence (number) of homozygous wild-types, heterozygous variants, and homozygous variants in CYP1A1 *MspI* polymorphisms to be 42.5% (34), 42.5% (34), and 15.0% (12), respectively, among 80 coke-oven workers (Wu *et al*, 1998). This distribution parallels the control population recruited for our present study, suggesting no potential selection bias was present.

In summary, this study found CYP1A1 *exon 7* (but not *MspI*) polymorphism to be a factor in elevated oesophageal cancer risk. This association suggests that carcinogen biotransformation may be a contributing factor to the etiology of oesophageal squamous-cell-carcinoma among the population in Taiwan.

## ACKNOWLEDGEMENTS

This research was supported by grants from the Taiwan National Science Council (NSC 90-2320-B-037-040 and NSC 90-2320-B-037-052), the Taiwan National Health Research Institute (NHRI-CN-IN-9007P), and the Faculty Research Innovation Fund of Kaohsiung Medical University (Drs TF Chen and OL Chen).

## REFERENCES

- Bartsch H, Nair U, Risch A, Rojas M, Wikman H, Alexandrov K (2000) Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. *Cancer Epidemiol Biomarkers Prev* **9**: 3–28
- Cascorbi I, Brockmoller J, Roots I (1996) A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility. *Cancer Res* **56**: 4965–4969
- Crofts F, Taioli E, Trachman J, Cosma GN, Currie D, Toniolo P, Garte SJ (1994) Functional significance of different human CYP1A1 genotypes. *Carcinogenesis* **15**: 2961–2963
- Hayashi S, Watanabe J, Kawarjiri K (1992) High susceptibility to lung cancer analyzed in terms of combined genotype P4501A1 and Mu-class glutathione-S-transferase genes. *Jpn J Cancer Res* **83**: 866–870
- Hori H, Kawano T, Endo M, Yuasa Y (1997) Genetic polymorphisms of tobacco- and alcohol-related metabolizing enzymes and human oesophageal squamous cell carcinoma susceptibility. *J Clin Gastroenterol* **25**: 568–575
- Kawarjiri K, Nakachi K, Imai K, Yoshii A, Shinoda N, Watanabe J (1990) Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P4501A1 gene. *FEBS Lett* **263**: 131–133
- Kiyohara C, Hirohata T, Inutsuka S (1996) The relationship between aryl hydrocarbon hydroxylase and polymorphisms of the CYP1A1 gene. *Jpn J Cancer Res* **87**: 18–24

- Lucas D, Menez C, Floch F, Gourlaouen Y, Sparfel O, Joannet I, Bodenez P, Jezequel J, Gouerou H, Berthou F, Bardou LG, Menez JF (1996) Cytochromes P4502E1 and P4501A1 genotypes and susceptibility to cirrhosis or upper aerodigestive tract cancer in alcoholic caucasians. *Alcohol Clin Exp Res* **20**: 1033–1037
- Morita S, Yano M, Shiozaki H, Tsujinaka T, Ebisui C, Morimoto T, Kishibuti M, Fujita J, Ogawa A, Taniguchi M, Inoue M, Tamura S, Yamazaki K, Kikkawa N, Mizunoya S, Monden M (1997) CYP1A1, CYP2E1 and GSTM1 polymorphisms are not associated with susceptibility to squamous-cell carcinoma of the esophagus. *Int J Cancer* **71**: 192–195
- Murray GI, Shaw D, Weaver RJ, McKay JA, Ewen SW, Melvin WT, Burke MD (1994) Cytochrome P450 expression in oesophageal cancer. *Gut* **35**: 599–603
- Nakachi K, Imai K, Hayashi S, Watanabe J, Kawarjiri K (1991) Genetic susceptibility to squamous cell carcinoma of the lung in relation to cigarette smoking dose. *Cancer Res* **51**: 5177–5180
- Nakajima T, Wang RS, Nimura Y, Pin YM, He M, Vainio H, Murayama N, Aoyama T, Iida F (1996) Expression of cytochrome P450s and glutathione S-transferases in human esophagus with squamous-cell carcinomas. *Carcinogenesis* **17**: 1477–1481
- Nimura Y, Yokoyama S, Fujimori M, Aoki T, Adachi W, Nasu T, He M, Ping YM, Iida F (1997) Genotyping of the CYP1A1 and GSTM1 genes in oesophageal carcinoma patients with special reference to smoking. *Cancer* **80**: 852–857
- Roth MJ, Dawsey SM, Wang G, Tangrea JA, Zhou B, Ratnasinghe D, Woodson KG, Olivero OA, Poirier MC, Frye BL, Taylor PR, Weston A (2000) Association between GSTM1\*0 and squamous dysplasia of the esophagus in the high risk region of Linxian, China. *Cancer Lett* **156**: 73–81
- van Lieshout EM, Roelofs HM, Dekker S, Mulder CJ, Wobbes T, Jansen JB, Peters WH (1999) Polymorphic expression of the glutathione S-transferase P1 gene and its susceptibility to Barrett's esophagus and oesophageal carcinoma. *Cancer Res* **59**: 586–589
- Wang AH, Sun CS, Li LS, Huang JY, Chen QS (2002) Relationship of tobacco smoking CYP1A1 GSTM1 gene polymorphism and oesophageal cancer in Xi'an. *World J Gastroenterol* **8**: 49–53
- Wu MT, Huang SL, Ho CK, Yeh YF, Christiani DC (1998) Cytochrome P450 1A1 MspI polymorphism and urinary 1-hydroxypyrene concentrations in coke-oven workers. *Cancer Epidemiol Biomarkers Prev* **7**: 823–829
- Xu X, Kelsey KT, Wiencke JK, Wain JC, Christiani DC (1996) Cytochrome P450 CYP1A1 MspI polymorphism and lung cancer susceptibility. *Cancer Epidemiol Biomark Prev* **5**: 687–692